Tadalafil and sildenafil are both phosphodiesterase type 5 inhibitors used in erectile-dysfunction treatment, but they are not interchangeable versions of the same pharmacokinetic profile. Tadalafil has a much longer terminal half-life, is not meaningfully affected by food and has both as-needed and once-daily ED frameworks, while sildenafil reaches its median peak concentration sooner in the fasted state and high-fat meals slow its absorption.
Those differences affect treatment timing more than the shared mechanism does. Current CIALIS labeling supports an erectile-response window extending up to 36 hours after as-needed tadalafil, whereas VIAGRA labeling uses a more discrete pre-sex administration window and pharmacodynamic studies found sildenafil erectile response for up to 4 hours, diminished compared with the response at 2 hours.
This comparison does not declare a winner or convert pharmacokinetic values into individualized treatment advice. Instead, it compares the two molecules across mechanism, Tmax, half-life, food effects, labeled ED regimens, indications, metabolism and safety while routing tadalafil-specific depth to dedicated pages such as tadalafil half-life, food effects and dosage frameworks.
The biggest practical differences are not that one molecule uses an entirely different erectile pathway, but that their pharmacokinetic profiles and U.S. labeling create different timing frameworks. Tadalafil persists much longer, while sildenafil reaches its median peak sooner and has a shorter terminal half-life.
Food is another important separator. Tadalafil absorption is not meaningfully influenced by food, whereas a high-fat meal delays sildenafil Tmax and reduces its peak concentration.
The table combines comparable current-label facts rather than comparing efficacy percentages taken from unrelated clinical trials.
| Feature | Tadalafil | Sildenafil |
|---|---|---|
| Drug class | PDE5 inhibitor | PDE5 inhibitor |
| Well-known ED brand | CIALIS | VIAGRA |
| Median Tmax | About 2 hours | About 1 hour fasting |
| Observed Tmax range | 30 minutes to 6 hours | 30 to 120 minutes fasting |
| Mean terminal half-life | 17.5 hours | About 4 hours |
| Food effect | Rate and extent of absorption not influenced by food | High-fat meal delays Tmax by about 60 minutes and lowers Cmax by about 29% |
| As-needed ED timing | Before anticipated sexual activity; patient counseling states at least 30 minutes beforehand | Usually about 1 hour before; labeled range 30 minutes to 4 hours before |
| Late erectile-response evidence | Improved erectile function shown up to 36 hours after dosing | Pharmacodynamic study showed effect up to 4 hours, diminished compared with 2 hours |
| Once-daily ED regimen | Yes | Not part of the VIAGRA ED label |
| BPH indication | Yes, in CIALIS labeling | No in VIAGRA labeling |
| PAH product context | Yes — separate tadalafil products such as ADCIRCA and TADLIQ | Yes — separate sildenafil products such as REVATIO |
| Sexual stimulation required for ED effect | Yes | Yes |
Both drugs enhance the nitric oxide-cGMP pathway by inhibiting phosphodiesterase type 5. During sexual stimulation, nitric oxide release increases cGMP in corpus cavernosal smooth muscle, and PDE5 inhibition slows cGMP breakdown so smooth-muscle relaxation and penile blood flow can be enhanced.
Neither tadalafil nor sildenafil creates an erection independently of sexual stimulation. This shared mechanism is why both drugs also share several class-level vasodilatory effects, contraindications and warnings.
Their major differences therefore emerge from pharmacokinetics, phosphodiesterase selectivity, product labeling and treatment framework rather than from a completely different erectile mechanism.
| Mechanism step | Tadalafil | Sildenafil |
|---|---|---|
| Primary target | PDE5 | PDE5 |
| Effect on cGMP | Reduces cGMP degradation | Reduces cGMP degradation |
| Requires sexual stimulation for ED effect | Yes | Yes |
| Automatic erection without stimulation | No | No |
Tadalafil and sildenafil differ across several PK dimensions, not only half-life. Tadalafil has slower median peak timing and substantially longer terminal persistence, while sildenafil is absorbed rapidly in the fasted state and forms an active circulating metabolite.
Absolute oral bioavailability is established for sildenafil but has not been determined for tadalafil. Both are highly protein bound and both depend substantially on hepatic CYP3A metabolism.
These values describe drug disposition and should not be converted directly into comparative efficacy claims.
| PK parameter | Tadalafil | Sildenafil |
|---|---|---|
| Tmax | 30 min–6 h; median 2 h | 30–120 min; median 60 min fasting |
| Terminal half-life | 17.5 h | About 4 h for sildenafil and major active metabolite |
| Absolute oral bioavailability | Not determined | Mean about 41% (range 25–63%) |
| Protein binding | About 94% | About 96% for sildenafil and major metabolite |
| Apparent / steady-state distribution volume | About 63 L apparent volume | About 105 L Vss |
| Major metabolic route | Predominantly CYP3A4 | Predominantly CYP3A4; CYP2C9 is a minor route |
| Major metabolite context | Observed metabolites are not expected to be pharmacologically active at measured concentrations | N-desmethyl metabolite is active and has about 50% of parent PDE5 potency in vitro |
| Food influence | No meaningful effect on rate or extent of absorption | High-fat meal slows absorption |
Sildenafil reaches its median maximum plasma concentration at about 60 minutes in the fasted state, compared with approximately 2 hours for tadalafil. That does not prove sildenafil universally begins working twice as fast, because Tmax measures the timing of peak plasma concentration rather than the first clinically useful erectile response.
CIALIS patient counseling notes that sexual activity may be possible from about 30 minutes after as-needed dosing, even though tadalafil's median Tmax is later. VIAGRA can likewise be taken as early as 30 minutes before sexual activity despite a median fasting Tmax of about 60 minutes.
This PK-versus-clinical distinction is explored in greater depth on the tadalafil onset page.
| Concept | Tadalafil | Sildenafil |
|---|---|---|
| Median Tmax | 2 h | 1 h fasting |
| Earliest label-related ED timing | At least 30 min before anticipated sexual activity | Can be taken 30 min before sexual activity |
| Tmax equals onset? | No | No |
Tadalafil's mean terminal half-life in healthy subjects is approximately 17.5 hours. Sildenafil and its major active metabolite have terminal half-lives of about 4 hours.
That difference helps explain tadalafil's longer concentration-time tail and the different planning frameworks found in ED labeling. It does not mean the erectile effect remains at one constant intensity for 17.5 hours, nor does a 4-hour sildenafil half-life define an exact 4-hour clinical cutoff.
For a deeper interpretation of tadalafil's 17.5-hour value, see what tadalafil half-life means.
| Half-life concept | Tadalafil | Sildenafil |
|---|---|---|
| Mean terminal half-life | 17.5 h | About 4 h |
| Longer concentration tail | Yes | Shorter relative to tadalafil |
| Half-life equals erectile duration | No | No |
Current CIALIS labeling states that as-needed tadalafil improved erectile function compared with placebo up to 36 hours after dosing. Patient counseling similarly notes that in most patients the ability to have sexual intercourse can remain improved for up to 36 hours.
VIAGRA pharmacodynamic studies evaluated erectile response over a shorter period. In one time-course study, an effect was observed for up to 4 hours, although the response at 4 hours was diminished compared with the response at 2 hours.
These are clinical-response observations, not direct conversions from the 17.5-hour and approximately 4-hour terminal half-lives. Tadalafil-specific duration evidence is examined on the duration page and the 36-hour evidence page.
| Timing concept | Tadalafil | Sildenafil |
|---|---|---|
| Terminal half-life | 17.5 h | ~4 h |
| Label / pharmacodynamic late-response evidence | Improved erectile function demonstrated up to 36 h | Effect observed up to 4 h in a time-course study, diminished vs 2 h |
| Continuous erection implied? | No | No |
| Sexual stimulation still required? | Yes | Yes |
Current CIALIS pharmacokinetics states that food does not influence the rate or extent of tadalafil absorption. This allows tadalafil's label to state that it may be taken without regard to food.
Sildenafil can also be taken with or without food, but a high-fat meal changes its absorption profile. Current VIAGRA labeling reports an average Tmax delay of about 60 minutes and an average Cmax reduction of 29% after a high-fat meal.
The distinction is therefore not that sildenafil cannot be taken with food; it is that a high-fat meal can make peak sildenafil exposure later and lower. Tadalafil's meal-specific PK is covered on the tadalafil food-effects page.
| Food comparison | Tadalafil | Sildenafil |
|---|---|---|
| May be taken with or without food | Yes | Yes |
| High-fat meal changes absorption rate | No meaningful label-described effect | Yes |
| Mean Tmax effect | No meaningful food-related shift | Delayed by about 60 min |
| Mean Cmax effect | No meaningful food-related change | Reduced about 29% |
For as-needed ED treatment, current CIALIS labeling uses 10 mg as the starting dose for most patients, with 5 mg and 20 mg as adjustment options based on efficacy and tolerability. Current VIAGRA labeling uses 50 mg for most patients, with 25 mg and 100 mg as adjustment options.
Those milligram values cannot be compared as if 50 mg sildenafil were 'five times stronger' than 10 mg tadalafil. Milligram numbers measure mass of different molecules and do not create a potency conversion.
Tadalafil dosing in its own clinical contexts is covered on the tadalafil dosage page.
| ED label feature | Tadalafil / CIALIS | Sildenafil / VIAGRA |
|---|---|---|
| Typical as-needed starting framework | 10 mg | 50 mg |
| Other labeled ED strengths used for adjustment | 5 mg and 20 mg | 25 mg and 100 mg |
| Maximum usual frequency | Once per day in most patients | Once per day |
| Milligram-for-milligram equivalence | No direct conversion | No direct conversion |
A numerical dose comparison is one of the easiest ways to misread tadalafil versus sildenafil. The molecules have different molecular properties, approved dose ranges, pharmacokinetics and product indications, so equal milligram amounts do not represent equal clinical exposure or equal effect.
This becomes even more obvious in PAH products, where sildenafil 20 mg and tadalafil 20 mg may both appear in product labeling but are used within very different treatment regimens. Shared numbers do not create interchangeability.
Tadalafil's own tablet-strength framework is explained on the tadalafil strengths page.
| Comparison shortcut | Accurate? |
|---|---|
| 20 mg tadalafil = 20 mg sildenafil | No |
| Higher milligram number means stronger PDE5 inhibitor | No |
| Dose must be interpreted within each product's label | Yes |
CIALIS has two distinct labeled ED frameworks: use as needed and once-daily treatment. The once-daily ED framework starts at 2.5 mg taken at approximately the same time each day and may be increased to 5 mg based on efficacy and tolerability.
VIAGRA's ED label is an as-needed framework rather than a once-daily ED maintenance regimen. Sildenafil does have scheduled dosing in separate PAH product labeling, but that should not be confused with a daily Viagra regimen for erectile dysfunction.
The distinction between tadalafil's two ED strategies is explored on the daily versus as-needed tadalafil page.
| ED treatment framework | Tadalafil / CIALIS | Sildenafil / VIAGRA |
|---|---|---|
| As-needed ED treatment | Yes | Yes |
| Once-daily labeled ED treatment | Yes | No |
| Daily treatment independent of sexual timing | Part of CIALIS ED labeling | Not part of VIAGRA ED labeling |
For as-needed tadalafil, patient counseling states that a tablet should be taken at least 30 minutes before anticipated sexual activity and that improved ability to have intercourse may persist for up to 36 hours. The label therefore supports a relatively broad response window rather than one narrow target hour.
VIAGRA is generally taken approximately 1 hour before sexual activity, with current labeling allowing administration from 30 minutes to 4 hours beforehand. This creates a more time-linked as-needed framework.
Neither timing model is inherently superior. Their significance depends on the treatment context rather than on a universal preference.
| Planning feature | Tadalafil | Sildenafil |
|---|---|---|
| As-needed advance timing | At least 30 min in CIALIS counseling | Usually ~1 h; permitted 30 min–4 h before sex |
| Broad late-response window | Up to 36 h demonstrated | Shorter response profile |
| Daily ED option removes pre-sex dose timing | Yes | No in VIAGRA labeling |
CIALIS is labeled for erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, and combined ED/BPH. VIAGRA is labeled for erectile dysfunction and does not carry a BPH indication.
Both active ingredients also appear in separate pulmonary arterial hypertension product contexts. Tadalafil is used in products such as ADCIRCA and TADLIQ, while sildenafil appears in products such as REVATIO.
The PAH use of tadalafil is covered separately on the pulmonary arterial hypertension page, while the BPH indication belongs on the tadalafil for BPH page.
| U.S. indication context | Tadalafil | Sildenafil |
|---|---|---|
| Erectile dysfunction | Yes — CIALIS / tadalafil ED products | Yes — VIAGRA / sildenafil ED products |
| BPH signs and symptoms | Yes — CIALIS | Not a VIAGRA indication |
| Combined ED + BPH | Yes — CIALIS | Not a VIAGRA indication |
| Pulmonary arterial hypertension | Yes — separate tadalafil PAH products | Yes — separate sildenafil PAH products |
The presence of pulmonary arterial hypertension indications for both active ingredients can create confusing search results. Tadalafil used as CIALIS for ED/BPH should not be treated as interchangeable with ADCIRCA or TADLIQ, and sildenafil used as VIAGRA for ED should not be treated as interchangeable with REVATIO.
PAH products use different labeled doses, schedules, formulations and clinical endpoints from ED products. Comparing CIALIS and VIAGRA therefore requires keeping the ED product framework separate from the broader identities of tadalafil and sildenafil.
Tadalafil's PAH brand context is covered in more detail on the Adcirca page.
| Active ingredient | ED product context | PAH product context |
|---|---|---|
| Tadalafil | CIALIS and generic tadalafil ED products | ADCIRCA, TADLIQ and applicable generic PAH products |
| Sildenafil | VIAGRA and generic sildenafil ED products | REVATIO and applicable generic sildenafil PAH products |
| Are ED and PAH dosing frameworks interchangeable? | No | No |
Tadalafil is metabolized predominantly by CYP3A4 to a catechol metabolite that undergoes further methylation and glucuronidation. Current tadalafil labeling states that the resulting metabolites are not expected to be pharmacologically active at observed concentrations.
Sildenafil is also cleared predominantly through CYP3A4, with CYP2C9 as a minor route. Its major circulating N-desmethyl metabolite has an in-vitro PDE5 potency approximately 50% that of sildenafil and contributes to the overall pharmacologic effect.
This shared CYP3A dependence means interacting drugs can matter for both molecules, but the exact exposure changes and label instructions are drug specific. Tadalafil-specific enzyme detail belongs on the tadalafil CYP3A4 page.
| Metabolic feature | Tadalafil | Sildenafil |
|---|---|---|
| Major CYP pathway | CYP3A4 | CYP3A4 |
| Additional important CYP route in label | Not emphasized as a comparable secondary route | CYP2C9 minor route |
| Major circulating metabolite pharmacology | Not expected to be pharmacologically active at observed concentrations | N-desmethyl metabolite is pharmacologically active |
| Active-metabolite terminal half-life | Not a major active-metabolite driver | About 4 h, similar to parent sildenafil |
Both molecules are selective PDE5 inhibitors, but their selectivity across other phosphodiesterases differs. Sildenafil is only about 10-fold more potent for PDE5 than retinal PDE6, and current VIAGRA labeling links this lower PDE5-versus-PDE6 selectivity to color-vision abnormalities at higher doses or exposures.
Tadalafil is approximately 700-fold more potent for PDE5 than PDE6, while it also inhibits PDE11 isoforms in vitro at therapeutic-range concentrations. Current CIALIS labeling states that the physiological role and clinical consequences of PDE11 inhibition in humans have not been defined.
It would therefore be inappropriate to claim that tadalafil's back pain is proven to result from PDE11 inhibition merely because the two appear in the same label.
| Selectivity feature | Tadalafil | Sildenafil |
|---|---|---|
| PDE5 vs PDE6 selectivity | About 700-fold | About 10-fold |
| Label interpretation of PDE6 | High PDE5 selectivity relative to retinal PDE6 | Lower selectivity linked to color-vision abnormalities |
| PDE11 | In-vitro inhibition occurs; clinical consequence undefined | Much greater selectivity for PDE5 than PDE11 |
| Can PDE11 inhibition be declared the proven cause of tadalafil back pain? | No | Not applicable |
Headache, dyspepsia, nasal symptoms and vasodilatory effects appear in the safety profiles of both PDE5 inhibitors. Tadalafil labeling also prominently includes back pain, myalgia and pain in the limb among common reactions, while VIAGRA labeling includes abnormal vision among its common adverse reactions.
These observations should not be turned into a percentage-by-percentage winner table because tadalafil and sildenafil trial programs differed in population, dose, design and duration. Cross-trial adverse-event percentages are not equivalent to randomized head-to-head comparison data.
Tadalafil's adverse-effect profile is covered on the tadalafil side-effects page.
| Safety pattern | Tadalafil labeling | Sildenafil labeling |
|---|---|---|
| Headache | Common | Common |
| Dyspepsia | Common | Common |
| Flushing / nasal congestion | Reported | Reported |
| Back pain / myalgia | Prominent in CIALIS common-reaction listing | Also reported in VIAGRA labeling |
| Abnormal vision | Not a defining common-reaction feature of CIALIS labeling | Included among common VIAGRA reactions |
| Can trial percentages be compared directly? | No | No |
Both CIALIS and VIAGRA are contraindicated with organic nitrates because PDE5 inhibition can potentiate nitrate-induced hypotension. Both labels also prohibit concomitant use with guanylate cyclase stimulators such as riociguat because of the risk of excessive blood-pressure lowering.
The longer persistence of tadalafil creates a different nitrate-management context from sildenafil. Current CIALIS labeling provides a specific 48-hour minimum before nitrate consideration in a life-threatening situation under close medical supervision, while VIAGRA labeling states that it is unknown when nitrates can be safely administered after sildenafil.
The tadalafil-specific nitrate evidence and the meaning of the 48-hour wording belong on the tadalafil and nitrates page.
| Contraindication / context | Tadalafil | Sildenafil |
|---|---|---|
| Organic nitrates | Contraindicated | Contraindicated |
| GC stimulators such as riociguat | Contraindicated | Contraindicated |
| Post-dose nitrate timing | CIALIS label gives specific emergency 48-hour minimum context | VIAGRA label states safe post-dose nitrate timing is unknown |
| Self-directed nitrate timing rule | Not appropriate | Not appropriate |
Tadalafil and sildenafil both have systemic vasodilatory properties. Their labels contain healthy-volunteer blood-pressure data as well as interaction studies involving nitrates, alpha-blockers and antihypertensive medicines.
Those studies used different doses, designs, positions and measurement methods, so comparing one tadalafil millimeter-of-mercury value directly with one sildenafil value would not establish which molecule is universally 'stronger' at lowering blood pressure. The clinically important comparison is that both require interaction-specific assessment.
Tadalafil's hemodynamic evidence is integrated on the tadalafil blood-pressure page.
| Blood-pressure concept | Tadalafil | Sildenafil |
|---|---|---|
| Systemic vasodilator | Yes | Yes |
| Nitrate hypotension potentiation | Yes | Yes |
| Alpha-blocker caution | Yes | Yes |
| Antihypertensive interaction context | Yes | Yes |
| Can separate healthy-volunteer BP studies establish a winner? | No | No |
Both tadalafil and sildenafil can add to the blood-pressure-lowering effect of alpha-blockers. Their labels emphasize hemodynamic stability before introducing PDE5 inhibition and cautious initiation when the treatments overlap.
Tadalafil has an additional BPH-specific issue because CIALIS itself is labeled for BPH, while VIAGRA is not. Current CIALIS labeling does not recommend tadalafil plus an alpha-blocker specifically for BPH treatment.
The tadalafil-specific agent studies and ED-versus-BPH distinction belong on the alpha-blocker interaction page.
| Alpha-blocker feature | Tadalafil | Sildenafil |
|---|---|---|
| Additive hypotension possible | Yes | Yes |
| Hemodynamic stability relevant | Yes | Yes |
| BPH-specific PDE5 label context | Yes | No VIAGRA BPH indication |
A high-fat meal can delay sildenafil's peak concentration by about one hour. That means the practical timing of sildenafil exposure can shift even though VIAGRA itself is permitted with or without food.
Tadalafil's absorption is not meaningfully influenced by food, so meal composition does not create the same labeled PK shift. Combined with tadalafil's longer half-life and broader response window, this produces a different timing profile rather than evidence of greater efficacy.
The distinction is particularly important when comparing convenience or predictability: these are pharmacokinetic characteristics, not measures of which drug works better for every patient.
| Planning variable | Tadalafil | Sildenafil |
|---|---|---|
| High-fat meal delays peak | No meaningful labeled effect | Yes, ~60 min mean Tmax delay |
| Long concentration persistence | Greater | Shorter |
| Does this prove higher efficacy? | No | No |
Both tadalafil and sildenafil demonstrated efficacy against placebo in their respective ED development programs. However, response percentages from one CIALIS trial should not simply be placed beside percentages from an unrelated VIAGRA trial and interpreted as a head-to-head efficacy result.
Clinical studies can differ in patient characteristics, endpoint definitions, dose, timing, run-in procedures and statistical methods. A fair superiority claim requires evidence designed for that comparison rather than arithmetic across unrelated labels.
For that reason, this page treats efficacy as established for both drugs while focusing its direct comparison on features that can be compared reliably from current labeling.
| Comparison method | Valid interpretation? |
|---|---|
| Both labels show efficacy vs placebo | Yes |
| Compare unrelated label response percentages as if randomized head-to-head | No |
| Use PK, food and labeled-regimen differences directly | Yes |
| Declare a universal efficacy winner from the labels | No |
Current product labeling does not establish one molecule as universally better. Tadalafil offers a longer pharmacokinetic profile, a broad as-needed response window, food-independent absorption and a labeled once-daily ED option; sildenafil offers a shorter PK profile with a more discrete as-needed timing framework and a median fasting Tmax of about one hour.
The two drugs also differ in food sensitivity, adverse-effect pattern, indications, drug-interaction details and the amount of time exposure persists after a dose. Those characteristics can be clinically relevant without constituting a universal ranking.
A comparison is therefore most accurate when it asks which characteristics differ, rather than attempting to name one winner for every patient.
| Comparison priority | Tadalafil characteristic | Sildenafil characteristic |
|---|---|---|
| Longer persistence | 17.5 h half-life; up-to-36-h response evidence | ~4 h half-life; shorter response profile |
| Meal independence | Food does not meaningfully affect absorption | High-fat meal slows absorption |
| Once-daily ED framework | Available | Not available in VIAGRA labeling |
| More discrete as-needed timing | Broad window | Usually centered around ~1 h before sex |
| Universal winner | No | No |
Several comparison shortcuts sound intuitive but are pharmacologically misleading. Milligram values are not equivalent, Tmax is not onset, half-life is not the same as clinical duration and a 36-hour tadalafil window does not mean a continuous erection.
It is also inaccurate to say sildenafil cannot be taken with food; the issue is specifically that a high-fat meal slows its absorption. Likewise, the fact that tadalafil lasts longer does not itself prove superior efficacy.
Keeping these distinctions explicit makes the comparison useful rather than merely promotional.
| Misunderstanding | Correct interpretation |
|---|---|
| Tadalafil 20 mg and sildenafil 20 mg are equivalent | No |
| Sildenafil Tmax of ~1 h means everyone feels an effect exactly at 1 h | No |
| Tadalafil half-life of 17.5 h means it works for exactly 17.5 h | No |
| 36-hour tadalafil means a 36-hour erection | No |
| Sildenafil must be taken fasting | No; high-fat food can delay absorption |
| Longer duration automatically means better efficacy | No |
| Both drugs have identical approved indications | No |
A useful comparison separates pharmacology from preference. Timing, meal effects, treatment schedule, labeled indications, interaction profile and adverse-effect pattern are all legitimate comparison dimensions, while cross-trial percentages and milligram arithmetic are much weaker shortcuts.
The checklist below summarizes the questions that meaningfully distinguish the two drugs without selecting treatment for an individual.
| Comparison question | Why it matters |
|---|---|
| Is a broad or shorter as-needed timing window being compared? | Half-life and late-response evidence differ substantially |
| Does meal timing matter? | High-fat meals alter sildenafil absorption but not tadalafil absorption |
| Is a once-daily ED framework relevant? | CIALIS has one; VIAGRA does not |
| Is BPH also part of the treatment context? | CIALIS has a BPH indication; VIAGRA does not |
| Is the discussion actually about PAH rather than ED? | Separate tadalafil and sildenafil PAH products use different labels |
| Are nitrates, riociguat or alpha-blockers present? | Both drugs have important class-level safety interactions |
| Are side-effect percentages being compared across unrelated trials? | Such percentages do not establish head-to-head superiority |
| Are milligram numbers being treated as equivalent potency? | Different molecules and regimens cannot be converted that way |
Tadalafil and sildenafil share the same core PDE5 mechanism and both require sexual stimulation for an erectile response, but their pharmacokinetics differ substantially. Tadalafil reaches median Tmax at about 2 hours and has a mean terminal half-life of 17.5 hours; sildenafil reaches median Tmax at about 1 hour fasting and has a terminal half-life of about 4 hours.
The practical consequences appear in food and timing. Tadalafil absorption is not meaningfully affected by food and as-needed CIALIS has erectile-response evidence extending up to 36 hours, while a high-fat meal delays sildenafil Tmax by about 60 minutes and sildenafil's label-described pharmacodynamic response declines across its shorter post-dose window.
Neither profile establishes a universal winner. Tadalafil additionally offers once-daily ED and BPH labeling, while sildenafil has its own ED and separate PAH product contexts; safety, interactions, adverse-effect patterns and individual clinical circumstances remain part of any meaningful comparison.
The largest pharmacokinetic difference is persistence. Tadalafil has a mean terminal half-life of about 17.5 hours, compared with about 4 hours for sildenafil, and tadalafil also has a broader labeled ED response window and a once-daily ED treatment option.
Cialis is a brand product containing tadalafil. Tadalafil is the active ingredient and also appears in generic and other product contexts.
Viagra contains sildenafil as its active ingredient. Sildenafil also appears in generic ED products and in separate pulmonary arterial hypertension products such as Revatio.
Tadalafil has the longer pharmacokinetic profile. Its mean terminal half-life is about 17.5 hours and CIALIS has erectile-response evidence up to 36 hours after as-needed dosing, while sildenafil has an approximately 4-hour terminal half-life and a shorter pharmacodynamic response profile.
Current CIALIS labeling states that as-needed tadalafil improved erectile function compared with placebo up to 36 hours after dosing. That is a response window, not a continuous erection or a guarantee of identical response throughout all 36 hours.
In a VIAGRA time-course pharmacodynamic study, erectile response was observed for up to 4 hours, but the response at 4 hours was diminished compared with the response at 2 hours. Its terminal half-life is also about 4 hours, although half-life and clinical duration are not the same measurement.
Sildenafil reaches its median peak sooner in the fasted state: about 60 minutes versus approximately 2 hours for tadalafil. Tmax measures peak plasma timing and should not be treated as identical to clinical onset.
Its median fasting Tmax is earlier, but that alone does not prove faster clinical onset in every person. Both labels allow ED use beginning around 30 minutes before sexual activity, and Tmax is a pharmacokinetic measurement rather than an onset measurement.
Yes. Current CIALIS labeling states that food does not meaningfully affect the rate or extent of tadalafil absorption.
Yes, but a high-fat meal slows sildenafil absorption. Current VIAGRA labeling reports an average Tmax delay of about 60 minutes and a 29% reduction in Cmax after a high-fat meal.
Tadalafil has less meal-related PK sensitivity because food does not meaningfully alter its absorption, whereas a high-fat meal slows sildenafil absorption. That pharmacokinetic difference does not by itself establish superior overall efficacy.
Yes. CIALIS has a once-daily ED framework using lower daily doses taken at approximately the same time each day, independent of the timing of sexual activity.
No. The U.S. VIAGRA ED label uses an as-needed regimen rather than a once-daily ED maintenance framework. Scheduled sildenafil dosing exists in separate PAH labeling and should not be confused with Viagra treatment for ED.
No. They are different molecules with different approved dose ranges and pharmacokinetic properties, so milligram values cannot be converted directly between tadalafil and sildenafil.
Yes. Both PDE5 inhibitors enhance the erectile NO-cGMP pathway during sexual stimulation and do not produce the intended erectile response simply by being present in the bloodstream.
Sildenafil has the clearer labeled food effect. A high-fat meal delays its Tmax and lowers Cmax, while tadalafil absorption is not meaningfully influenced by food.
Their profiles overlap, including headache, dyspepsia, flushing and nasal symptoms, but they are not identical. Tadalafil labeling prominently includes back pain and myalgia, while abnormal vision is a common reaction in VIAGRA labeling.
Current VIAGRA labeling notes that sildenafil has relatively lower selectivity for PDE5 over retinal PDE6 and links that property to color-vision abnormalities observed at higher doses or exposures.
Yes. Both drugs can potentiate nitrate-induced hypotension and are contraindicated with organic nitrates. The post-dose management language differs between their labels because their pharmacokinetic profiles are different.
Their product labels do not support combining PDE5 inhibitors for ED, and the safety and efficacy of such combinations have not been established. Each drug should remain within its own prescribed treatment framework rather than being stacked for a stronger effect.
Current labeling does not establish a universal winner. Tadalafil and sildenafil differ in half-life, food effects, timing, daily-versus-as-needed options, indications and adverse-effect patterns, so a meaningful comparison is based on those characteristics rather than a single best-drug ranking.